Massimo Cristofanilli, MD

Massimo Cristofanilli, MD

Oncology in Chicago, IL

Hide Show

Speaks English and Italian


 (312) 695-0990

Contact


Hide Show

Office Hours

Monday:
8:00 am - 5:00 pm
Tuesday:
8:00 am - 5:00 pm
Wednesday:
8:00 am - 2:00 pm
Thursday:
9:00 am - 5:00 pm
Friday:
9:00 am - 5:00 pm
Saturday:
Closed
Sunday:
Closed
Hide Show

About Dr. Cristofanilli


Dr. Massimo Cristofanilli, MD is an oncologist in Chicago, Illinois. He is currently licensed to practice medicine in Illinois and Pennsylvania.
He is an expert in the research and management of hormone-receptor positive metastatic breast cancer and IBC. He is a pioneer in liquid biopsy including CTCs and ctDNA research and clinical applications. He leads the Precision Medicine program at the Lurie Cancer Center, NU aimed at application of NGS and omics for patients' care.

Qualifications and Experience



Hide Show

Education & Training

University of Texas Health Science Center - Houston
Fellowship, Medical Oncology, 1996 - 1999

Mount Sinai School of Medicine
Residency, Internal Medicine, 1993 - 1996

Sapienza University of Rome
Class of 1986

█████ ████ ███
▄▄▄▄ ▄▄▄▄▄▄ ▄▄▄▄▄ ▄▄ ▄▄▄▄▄
▄▄▄▄▄▄▄ ▄▄▄▄▄▄ ▄▄▄
Hide Show

Certifications

American Board of Internal Medicine
Medical Oncology

█████ ████ ███
▄▄▄▄ ▄▄▄▄▄▄ ▄▄▄▄▄ ▄▄ ▄▄▄▄▄
▄▄▄▄▄▄▄ ▄▄▄▄▄▄ ▄▄▄
Hide Show

Medical Licenses

IL State Medical License
2015 - 2020

PA State Medical License
2010 - 2016

TX State Medical License
1997 - 2010

█████ ████ ███
▄▄▄▄ ▄▄▄▄▄▄ ▄▄▄▄▄ ▄▄ ▄▄▄▄▄
▄▄▄▄▄▄▄ ▄▄▄▄▄▄ ▄▄▄
Hide Show

Awards

Patient-Centered Specialty Practice Recognition Program
National Committee for Quality Assurance, 2014-2017

Philadelphia Magazine
Castle Connolly, 2012-2014

America's Top Doctors
Castle Connolly, 2012-2014

CMS Meaningful Use Stage 1 Certification
Allscripts Enterprise EHR, Allscripts, 2013

America's Top Doctors for Cancer
Castle Connolly, 2012-2013

Lifetime Achievement Award for Ethics and Creativity in Medical Research
Giovan Giacomo Giordano NIAF, 2012

Scientific Research Award
American Cancer Society, Southeast Region, 2012

Best Doctor
Philadelphia Magazine, 2012-2013

Humanitarian Award Finalist
ASCO, 2011

Best Doctor
US News & World Report, 2009

█████ ████ ███
▄▄▄▄ ▄▄▄▄▄▄ ▄▄▄▄▄ ▄▄ ▄▄▄▄▄
▄▄▄▄▄▄▄ ▄▄▄▄▄▄ ▄▄▄
Hide Show

Professional Memberships

American College of Physicians - ACP
Fellow

American Association for Cancer Research - AACR
Member

American Society of Clinical Oncology - ASCO
Member

█████ ████ ███
▄▄▄▄ ▄▄▄▄▄▄ ▄▄▄▄▄ ▄▄ ▄▄▄▄▄
▄▄▄▄▄▄▄ ▄▄▄▄▄▄ ▄▄▄
Hide Show

Publications



PubMed

Emerging Role of Genomics and Cell-Free DNA in Breast Cancer.
Current treatment options in oncology
Gerratana, L., Davis, A. A., Shah, A. N., Lin, C., Corvaja, C., Cristofanilli, M.
7/1/2019

Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol.
Jiang, Z.,Li, W.,Hu, X.,Zhang, Q.,Sun, T.,Cui, S.,Wang, S.,Ouyang, Q.,Yin, Y.,Geng, C.,Tong, Z.,Cheng, Y.,Pan, Y.,Sun, Y.,Wang, H.,Ouyang, T.,Gu, K.,Feng, J.,Wang, X.,Wang, S.,Liu, T.,Gao, J.,Cristofanilli, M.,Ning, Z.,Lu, X.
5/1/2019

Patient-centered engagement and symptom/toxicity monitoring in the new era of tumor next-generation sequencing and immunotherapy: The OncoTool and OncoPRO platforms.
Cancer
Yanez, B.,Bouchard, L. C.,Cella, D.,Sosman, J. A.,Kircher, S. M.,Mohindra, N. A.,Cristofanilli, M.,Penedo, F. J.
4/30/2019

See All

Journal Article

Antitumor Response of an ERBB2 Amplified Inflammatory Breast Carcinoma With EGFR Mutation to the EGFR-TKI Erlotinib
Clin Breast Cancer
Ali SM, Alpaugh RK, Buell JK, Stephens PJ, Yu JQ, Wu H, Hiemstra CN, Miller VA, Lipson D, Palmer GA, Ross JS, Cristofanilli M
2/1/2014

Emergence of constitutively active estrogen receptor-alpha mutations in pretreated advanced estrogen receptor positive breast cancer
Clin Cancer Res
Jeselsohn R, Yelensky R, Buchwalter G, Frampton GM, Meric-Bernstam F, Gonzalez-Angulo AM, Ferrer-Lozano J, Perez-Fidalgo A, Cristofanilli M, Gomez H, Arteaga CL, Giltnane J, Balko JM, Cronin MT, Jarosz M, Sun J, Hawryluk M, Lipson D, Otto G, Ross J, Dvir A, Soussan-Gutman L, Wolf I, Rubinek T, Gilmore L, Schnitt SJ, Come SE, Pusztai L, Stephens PJ, Brown M, Miller VA
1/7/2014

The Third International Inflammatory Breast Cancer Conference
Breast Cancer Res
van Golen KL, Cristofanilli M
11/5/2013

█████ ████ ███
▄▄▄▄ ▄▄▄▄▄▄ ▄▄▄▄▄ ▄▄ ▄▄▄▄▄
▄▄▄▄▄▄▄ ▄▄▄▄▄▄ ▄▄▄
Hide Show

Press Mentions



CytoDyn Announces FDA Clearance to Proceed with Phase 2 Study of Leronlimab (PRO 140) and Regorafenib as a Combination Therapy for Metastatic Colorectal Cancer
FinancialBuzz · September 09, 2019
...our Phase 1b/2 trial using leronlimab in treatment-naïve mTNBC patients is under the supervision of Massimo Cristofanilli, M.D., professor of Medicine in the Division of Hematology/Oncology at Northwestern University Fein...

Patient Treated with Leronlimab (PRO 140) for Metastatic Triple-Negative Breast Cancer Under Emergency IND, Launching CytoDyn into Oncology
Let Life Happen · August 30, 2019
...to the Phase 1b/2 trial with leronlimab for treatment-naïve mTNBC patients under the supervision of Massimo Cristofanilli, M.D., who is an expert in translational research treatment of patients with mTNBC and professor of...

CytoDyn Files a Phase 2 Protocol with the FDA for Leronlimab (PRO 140) and Regorafenib as a Combination Therapy for Metastatic Colorectal Cancer
FinancialBuzz · August 08, 2019
...our Phase 1b/2 trial using leronlimab in treatment-naïve mTNBC patients is under the supervision of Massimo Cristofanilli, M.D. professor of Medicine in the Division of Hematology/Oncology at Northwestern University Feinb...